AnGes, Inc.

4563

JP3127700007

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
49 ^JPY	0.00%		-2.00%	-31.94%

Jan. 19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
Jan. 18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

Mybiotics Pharma LTD announced that it has received $0.5 million in funding from AnGes, Inc.

November 27, 2022

Mybiotics Pharma LTD announced that it has issued convertible bonds for gross proceeds of $500,000 on November 28, 2022. The transaction included participation from AnGes, Inc.

Latest news about AnGes, Inc.

Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	Jan. 19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18	CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	Nov. 14	CI
Tupperware Brands Corporation : Plastic is fantastic	23-08-08
AnGes, Inc. announced that it has received Â¥8.481467 million in funding	23-07-11	CI
AnGes, Inc. announced that it expects to receive Â¥8.481467 million in funding	23-06-25	CI
Forex: A dead cat bounce?	23-05-15
AnGes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
AnGes, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Mybiotics Pharma LTD announced that it has received $0.5 million in funding from AnGes, Inc.	22-11-27	CI
Eiger Biopharmaceuticals Inc. and AnGes Inc. Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® in Japan	22-05-10	CI
AnGes, Inc.(TSE:4563) dropped from S&P Japan 500	22-03-22	CI
Etsy, Inc: Great opportunity or distorted reality?	22-01-31
AnGes, Inc. Announces Results of Phase 1/2 and Phase 2/3 Clinical Trials	21-11-05	CI
AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm	21-03-23	CI
Meiji : Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate	21-03-22	RE
AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm	21-03-07	CI
AnGes, Inc. completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.	20-12-14	CI
AnGes : Japan's AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine	20-12-07	RE
AnGes, Inc. signed an agreement to acquire Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others for approximately $110 million.	20-11-08	CI
Shionogi : REFILE-Japan's Shionogi readies COVID-19 vaccine for December trial- CEO	20-10-28	RE
AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey	20-10-15	CI
AnGes, Inc.(TSE:4563) added to S&P Japan 500	20-09-23	CI
Factbox: The race for a coronavirus vaccine	20-09-15	RE
AnGes, Inc. and Brickell Biotech, Inc. Announce Collaboration Agreement for the Development of A Novel DNA Vaccine Candidate for COVID-19 in the U.S	20-09-08	CI

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
ANGES, INC.	-31.94%	62.66M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

AnGes, Inc.

Equities

4563

JP3127700007

Biotechnology & Medical Research

Mybiotics Pharma LTD announced that it has received $0.5 million in funding from AnGes, Inc.

Latest news about AnGes, Inc.

Chart AnGes, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs